Results 61 to 70 of about 1,443,667 (357)
Improving antibody language models with native pairing [PDF]
arXiv, 2023 Current antibody language models are limited by their use of unpaired antibody sequence data and the biases in publicly available antibody sequence datasets, which are skewed toward antibodies against a relatively small number of pathogens. A recently published dataset (by Jaffe, et al) of approximately 1.6 x 10^6 natively paired human antibody ...
arxiv
BloodBispecific antibodies (BsAb) that target CD3 and CD20 represent a new milestone in the treatment of patients with B-cell non-Hodgkin lymphoma. These drugs have demonstrated remarkable single-agent activity in heavily pretreated patients, and at least ...
J. Crombie +32 more
semanticscholar +1 more source
When Two are Better than One: Modeling the Mechanisms of Antibody Mixtures [PDF]
, 2019 It is difficult to predict how antibodies will behave when mixed together, even after each has been independently characterized. Here, we present a statistical mechanical model for the activity of antibody mixtures that accounts for whether pairs of antibodies bind to distinct or overlapping epitopes.
arxiv +1 more source
AntiBARTy Diffusion for Property Guided Antibody Design [PDF]
arXiv, 2023 Over the past decade, antibodies have steadily grown in therapeutic importance thanks to their high specificity and low risk of adverse effects compared to other drug modalities. While traditional antibody discovery is primarily wet lab driven, the rapid improvement of ML-based generative modeling has made in-silico approaches an increasingly viable ...
arxiv
Blood Advances, 2020 B-cell maturation antigen (BCMA), a member of the tumor necrosis factor family of receptors, is predominantly expressed on the surface of terminally differentiated B cells.
K. Pillarisetti +14 more
semanticscholar +1 more source
A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities
Frontiers in Immunology, 2021 Therapeutic monoclonal antibodies (mAbs) blocking immune checkpoints have been mainly used as monotherapy. Recently, combination therapy targeting multiple immune checkpoints has recently been explored to increase anti-cancer efficacy.
Xiaohui Cui +15 more
semanticscholar +1 more source
npj Systems Biology and Applications, 2020 Mosunetuzumab, a T-cell dependent bispecific antibody that binds CD3 and CD20 to drive T-cell mediated B-cell killing, is currently being tested in non-Hodgkin lymphoma.
I. Hosseini +6 more
semanticscholar +1 more source
A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand
Science Advances, 2021 CCW702 is a bispecific antibody that combines the specificity of an imaging ligand with the potency of a T cell immunotherapy. Despite the development of next-generation antiandrogens, metastatic castration-resistant prostate cancer (mCRPC) remains ...
S. C. Lee +22 more
semanticscholar +1 more source
Bispecific antibodies in cancer immunotherapy [PDF]
Current Opinion in Biotechnology, 2020 Among antibody-based cancer therapies, bispecific antibodies (biAbs) have gained momentum in preclinical and clinical investigations following the regulatory approvals of the trailblazing T-cell engaging biAb (T-biAb) blinatumomab. Discussed herein are recent strategies that aim at boosting the potency and mitigating the toxicity of T-biAbs, broadening
openaire +3 more sources
European Journal of Immunology, Volume 53, Issue 1, January 2023., 2023 B lineage cells have been identified as therapeutic targets in autoimmune diseases. In the current review article, we provide an overview of novel strategies to target B lineage cells in autoimmune diseases, with a focus on inflammatory rheumatic diseases.
Ana Merino‐Vico +3 more
wiley +1 more source